Rosumore EZ 40 Tablet combines Rosuvastatin 40mg and Ezetimibe 10mg, a clinically proven therapy for lowering LDL cholesterol, total cholesterol, and triglycerides. This combination improves lipid profiles and reduces the risk of atherosclerosis and cardiovascular events.
Rosuvastatin, a high-potency statin, inhibits cholesterol synthesis in the liver, while Ezetimibe reduces intestinal cholesterol absorption. Together, they provide enhanced lipid-lowering efficacy for patients requiring dual-action therapy.
This tablet is commonly prescribed in patients with mixed dyslipidemia, statin-resistant hypercholesterolemia, or high cardiovascular risk. Its efficacy and tolerability make it a preferred choice among cardiologists and general physicians.
Adding Rosumore EZ 40 Tablet to your cardiology and lipid-management segment strengthens your product portfolio, offering opportunities in hospital supply, pharmacy distribution, institutional tenders, export markets, and third-party manufacturing. Its high clinical demand ensures consistent turnover and profitability for distributors.